RDB15489 - pENTER-EGFR Del19

Resource data sheet
Prev.

pENTER-EGFR Del19

Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-activating mutation.


Catalog number	RDB15489
Resource name	pENTER-EGFR Del19
Clone info.	Gateway(R) entry vector of human epidermal growth factor receptor (EGFR) mutant, deletion in exon 19, EGFR-activating mutation. cDNA was obtained from HCC-827 cells. Expression was confirmed by the depositor with western blotting after cloned into pLenti6.3 vector (by LR clonase II reaction).
Vector backbone	pENTR (plasmid)
Size of vector backbone	2.6 kb
Selectable markers	Kan^r
Gene/insert name	human EGFR cDNA
Depositor	Katayama, Ryohei \|
Other clones in our bank	human EGFR (NCBI Gene 1956) \|

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.

Terms and conditions set forth by the DEPOSITOR In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Uchibori, K et al. Nat. Commun. 8: 14768, 2017)

Ordering Please visit Information of Request for Distribution.
Order form [Credit Card Payment] [Bank Transfer or Check Payment]
Material Transfer Agreement (MTA) [Word]

Remarks
Gateway® Entry clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.

Distribution information (domestic users) [open/close]

Terms and conditions set forth by the DEPOSITOR	In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Uchibori, K et al. Nat. Commun. 8: 14768, 2017)
Ordering	Please visit Information of Request for Distribution. Order form [Credit Card Payment] [Bank Transfer or Check Payment] Material Transfer Agreement (MTA) [Word]
Remarks	Gateway® Entry clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.

提供条件	利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Uchibori, K et al. Nat. Commun. 8: 14768, 2017)。
提供依頼	手続きの詳細は、「提供申込みについて」をご覧ください。提供依頼書 [Word] 提供同意書 [Word]
備考	Gateway®テクノロジーを用いたエントリークローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。

Catalog #	Resource name	Shipping form	Fee (non-profit org.)
RDB15489	pENTER-EGFR Del19	DNA solution

Ordering Information [in Japanese] [in English]

References and tips

Electronic file

Original reference

original	Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083.

Further references such as user reports and related articles (go to bottom)

Sequence information

RIKEN BRC has sequenced portions of this material for quality test. Primers and the results are shown below.

Data are summerized on test sheet below.

Test sheet	RDB15489_A7K8p1-1.pdf

Nucleotide sequence of a portion of this resource (if available).

Region: rrnB T1 ter, attL1, insert 5' \| Primer: rrnBT1ter_F2 \| Sequence: RDB15489_A7K8a.seq
>D04925A2_A7K8_2_rrnBT1ter_F2_B04_04_ABI24.ab1 1 AACGCCAAGG TCTTCCGACT GAGCCTTTCG TTTTATTTGA TGCCTGGCAG TTCCCTACTC 61 TCGCGTTAAC GCTAGCATGG ATGTTTTCCC AGTCACGACG TTGTAAAACG ACGGCCAGTC 121 TTAAGCTCGG GCCCCAAATA ATGATTTTAT TTTGACTGAT AGTGACCTGT TCGTTGCAAC 181 AAATTGATGA GCAATGCTTT TTTATAATGC CAACTTTGTA CAAAAAAGCA GGCTCCGCGG 241 CCGCCCCCTT CACCATGCGA CCCTCCGGGA CGGCCGGGGC AGCGCTCCTG GCGCTGCTGG 301 CTGCGCTCTG CCCGGCGAGT CGGGCTCTGG AGGAAAAGAA AGTTTGCCAA GGCACGAGTA 361 ACAAGCTCAC GCAGTTGGGC ACTTTTGAAG ATCATTTTCT CAGCCTCCAG AGGATGTTCA 421 ATAACTGTGA GGTGGTCCTT GGGAATTTGG AAATTACCTA TGTGCAGAGG AATTATGATC 481 TTTCCTTCTT AAAGACCATC CAGGAGGTGG CTGGTTATGT CCTCATTGCC CTCAACACAG 541 TGGAGCGAAT TCCTTTGGAA AACCTGCAGA TCATCAGAGG AAATATGTAC TACGAAAATT 601 CCTATGCCTT AGCAGTCTTA TCTAACTATG ATGCAAATAA AACCGGACTG AAGGAGCTGC 661 CCATGAGAAA TTTACAGGAA ATCCTGCATG GCGCCGTGCG GTTCAGCAAC AACCCTGCCC 721 TGTGCAATGT GGAGAGCATC CAGTGGCGGG ACATAGTCAG CAGTGACTTT CTCAGCAACA 781 TGTCGATGGA CTTCCAGAAC CACCTGGGCA GCTGCCAAAA GTGTGATCCA AGCTGTCCCA 841 ATGGGAGCTG CTGGGGTGCA GGAGAGGAGA ACTGCCAGAA ACTGACCAAA ATCATCTGTG 901 CCCAGCAGTG CTCCGGGCGC TGCCGTGGCA AGTCCCCCCA GTGACTGCTG CCACAACCAG 961 TGTGCTGCAG GCTGCACAGG CCCCCCGGGA GAGCGACTGC CCTGGTCTGC CCGCAAATTC 1021 CGAGACGAAA GCCACGTGCA AAGGACACCC TGCCCCCCCC CACTCATGCT TCTACAAACC 1081 CCCACCACGT ACAAGATTGG ATGATGAAAT CCCGAAGGTC AAAATAACAG GCCTTTTG //
Region: attL2, insert 3' \| Primer: pDONR_R \| Sequence: RDB15489_A7K8b.seq
>D04925A2_A7K8_2_EGFR-F5_B09_06_ABI24.ab1 1 AACGTAATCG TCATCGCCAC TGGGATGGTG GGGGCCCTCC TCTTGCTGCT GGTGGTGGCC 61 CTGGGGATCG GCCTCTTCAT GCGAAGGCGC CACATCGTTC GGAAGCGCAC GCTGCGGAGG 121 CTGCTGCAGG AGAGGGAGCT TGTGGAGCCT CTTACACCCA GTGGAGAAGC TCCCAACCAA 181 GCTCTCTTGA GGATCTTGAA GGAAACTGAA TTCAAAAAGA TCAAAGTGCT GGGCTCCGGT 241 GCGTTCGGCA CGGTGTATAA GGGACTCTGG ATCCCAGAAG GTGAGAAAGT TAAAATTCCC 301 GTCGCTATCA AGACATCTCC GAAAGCCAAC AAGGAAATCC TCGATGAAGC CTACGTGATG 361 GCCAGCGTGG ACAACCCCCA CGTGTGCCGC CTGCTGGGCA TCTGCCTCAC CTCCACCGTG 421 CAACTCATCA CGCAGCTCAT GCCCTTCGGC TGCCTCCTGG ACTATGTCCG GGAACACAAA 481 GACAATATTG GCTCCCAGTA CCTGCTCAAC TGGTGTGTGC AGATCGCAAA GGGCATGAAC 541 TACTTGGAGG ACCGTCGCTT GGTGCACCGC GACCTGGCAG CCAGGAACGT ACTGGTGAAA 601 ACACCGCAGC ATGTCAAGAT CACAGATTTT GGGCTGGCCA AACTGCTGGG TGCGGAAGAG 661 AAAGAATACC ATGCAGAAGG AGGCAAAGTG CCTATCAAGT GGATGGCATT GGAATCAATT 721 TTACACAGAA TCTATACCCA CCAGAGTGAT GTCTGGAGCT ACGGGGTGAC CGTTTGGGAG 781 TTGATGACCT TTGGATCCAA GCCATATGAC GGAATCCCTG CCAGCGAGAT CTCCTCCATC 841 CTGGAGAAAG GAGAACGCCT CCCTCAGCCA CCCATATGTA CCATCGATGT CTACATGATC 901 ATGGTCAAGT GCTGGATGAT AGACGCAGAT AGTCGCCCAA AGTTCCGTGA GTTGATCATC 961 GAAATTCTCC AAAATGGCCC GAGACCCCCC AGCGCTACCC TTTGTCATTC AGGGGGATGA 1021 AGAATGCATT TGCCAGTCCC TACAGACTCG ACCTTCCTAC GTGCCTGATG TATGAAGAAG 1081 ACATTGACGA ACGTGAATGG ATGACCGACC GAGGT //
Region: insert middle region (del19) \| Primer: EGFR-F5 \| Sequence: RDB15489_A7K8c.seq
>D04925A2_A7K8_2_EGFR-F5_B09_06_ABI24.ab1 1 AACGTAATCG TCATCGCCAC TGGGATGGTG GGGGCCCTCC TCTTGCTGCT GGTGGTGGCC 61 CTGGGGATCG GCCTCTTCAT GCGAAGGCGC CACATCGTTC GGAAGCGCAC GCTGCGGAGG 121 CTGCTGCAGG AGAGGGAGCT TGTGGAGCCT CTTACACCCA GTGGAGAAGC TCCCAACCAA 181 GCTCTCTTGA GGATCTTGAA GGAAACTGAA TTCAAAAAGA TCAAAGTGCT GGGCTCCGGT 241 GCGTTCGGCA CGGTGTATAA GGGACTCTGG ATCCCAGAAG GTGAGAAAGT TAAAATTCCC 301 GTCGCTATCA AGACATCTCC GAAAGCCAAC AAGGAAATCC TCGATGAAGC CTACGTGATG 361 GCCAGCGTGG ACAACCCCCA CGTGTGCCGC CTGCTGGGCA TCTGCCTCAC CTCCACCGTG 421 CAACTCATCA CGCAGCTCAT GCCCTTCGGC TGCCTCCTGG ACTATGTCCG GGAACACAAA 481 GACAATATTG GCTCCCAGTA CCTGCTCAAC TGGTGTGTGC AGATCGCAAA GGGCATGAAC 541 TACTTGGAGG ACCGTCGCTT GGTGCACCGC GACCTGGCAG CCAGGAACGT ACTGGTGAAA 601 ACACCGCAGC ATGTCAAGAT CACAGATTTT GGGCTGGCCA AACTGCTGGG TGCGGAAGAG 661 AAAGAATACC ATGCAGAAGG AGGCAAAGTG CCTATCAAGT GGATGGCATT GGAATCAATT 721 TTACACAGAA TCTATACCCA CCAGAGTGAT GTCTGGAGCT ACGGGGTGAC CGTTTGGGAG 781 TTGATGACCT TTGGATCCAA GCCATATGAC GGAATCCCTG CCAGCGAGAT CTCCTCCATC 841 CTGGAGAAAG GAGAACGCCT CCCTCAGCCA CCCATATGTA CCATCGATGT CTACATGATC 901 ATGGTCAAGT GCTGGATGAT AGACGCAGAT AGTCGCCCAA AGTTCCGTGA GTTGATCATC 961 GAAATTCTCC AAAATGGCCC GAGACCCCCC AGCGCTACCC TTTGTCATTC AGGGGGATGA 1021 AGAATGCATT TGCCAGTCCC TACAGACTCG ACCTTCCTAC GTGCCTGATG TATGAAGAAG 1081 ACATTGACGA ACGTGAATGG ATGACCGACC GAGGT //

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

original	Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083.

2019.09.20

GNP_filter3_RDBDEP_html_190816.pl